On June 17, 2020, Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived-biopharmaceutical company headquartered in Rehovot, Israel, provided an update on its development of a plasma-derived immunoglobulin G (IgG) product for coronavirus 2019 (COVID-19) disease. Kamada (https://www.kamada.com/) completed manufacturing of the first batch of its plasma-derived IgG product for COVID-19, utilizing the Company’s approved proprietary IgG platform technology, and additional production is ongoing. The initial vials are available for compassionate use in Israel. In addition, Kamada’s proposed clinical protocol for a Phase 1/2 clinical trial was submitted to the Israeli Ministry of Health, and the Company expects to initiate the study during the third quarter of this year. In order to expand its clinical development program to the U.S., Kamada, with the support of Kedrion Biopharma (https://www.kedrion.us/), intends to conduct a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) early in the third quarter in order to obtain FDA’s acceptance of the proposed clinical development program. Pursuant to the company’s global collaboration agreement with Kedrion for the development, manufacturing, and distribution of the plasma-derived IgG product for COVID-19, Kedrion is currently collecting COVID-19 convalescent plasma from U.S. recovered patients that will be used by Kamada to manufacture additional batches of the product. Kedrion is collecting the plasma, through its plasma business unit, KEDPLASMA, at 23 FDA-approved centers across the United States. “We are extremely pleased with the rapid and important progress achieved to date in advancing our plasma-derived IgG product for COVID-19,” said Amir London, Kamada’s Chief Executive Officer.
Login Or Register To Read Full Story